Business Context and Reporting Period
This Form 8-K Current Report was filed by Atricure, Inc. on March 21, 2017. The filing addresses corporate governance changes, specifically the appointment of new directors and the departure of existing directors effective March 21, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the composition of the Board of Directors:
- Appointments: Regina Groves and B. Kristine Johnson were appointed as directors, effective March 21, 2017, serving until the next Annual Meeting of Stockholders. Both are deemed independent directors.
- Departures: Michael D. Hooven and Karen P. Robards informed the Board they will not stand for re-election at the Annual Meeting of Stockholders in May 2017.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It includes biographical details highlighting the new directors' experience:
- Regina Groves: Former CEO of REVA Medical, Inc., with extensive experience at Medtronic in cardiac rhythm and heart failure divisions, including market re-entry strategies and product launches.
- B. Kristine Johnson: President of Affinity Capital Management since 2000, with 17 years of prior experience at Medtronic in various executive roles.
Compensation for the new directors will follow the Company's policies for non-employee directors. No unusual items or contingencies were disclosed.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed directors (Regina Groves and B. Kristine Johnson) against NASDAQ listing standards.
- Confirm the exact date of the Annual Meeting of Stockholders in May 2017 to determine the tenure of the departing directors.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for these board changes.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial performance metrics.